Simcere Pharmaceutical Group Limited (Stock code: 2096) has announced that on January 26, 2026, its subsidiary, Jiangsu Simcere Pharmaceutical Co., Ltd., entered into an exclusive licensing agreement with Boehringer Ingelheim for SIM0709, a TL1A/IL-23p19 bispecific antibody aimed at treating inflammatory bowel disease outside of Greater China.

Under the agreement, an upfront payment of EUR42 million will be made to Simcere Pharmaceutical Group Limited, with further development, regulatory, and sales milestones of up to EUR1,016 million. Tiered royalties on net sales outside Greater China are also included.

SIM0709 is a humanized bispecific antibody developed with the company’s proprietary multi-specific antibody platform. It targets two core pathways, tumor necrosis factor ligand superfamily member 15 (TL1A) and interleukin-23 (IL-23), which are involved in the onset and progression of inflammatory bowel disease. The bispecific antibody has demonstrated superior synergistic performance in both in vitro and in vivo studies, surpassing the combination of the two corresponding monotherapies.